CRISPR Therapeutics, which is developing cures for genetic diseases based on CRISPR-Cas9 technology, filed on Friday with the SEC to raise up to $90 million in an initial public offering.
The Basel, Switzerland-based company was founded in 2013 and booked $2 million in sales for the 12 months ended June 30, 2016. It plans to list on the Nasdaq under the symbol CRSP. Citi, Piper Jaffray and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.
